Sugi Predict

Sugi Predict / Compounds / SCHEMBL1670331

SCHEMBL1670331

SCHEMBL1670331

CC(C)(C)OC(=O)N1CCN(C(=O)[C@H]2CC[C@H](Cn3c(=O)[nH]c4ccccc4c3=O)CC2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 6/20 0.70
▸ HSD17B10 Q99714 3/20 0.70
▸ SMN1; SMN2 Q16637 8/20 0.69
▸ LMNA P02545 6/20 0.69
▸ ALDH1A1 P00352 3/20 0.69
▸ MEN1 O00255 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ ALOX12 P18054 1/20 0.69
▸ TSHR P16473 3/20 0.63
▸ HTT P42858 4/20 0.61
▸ USP2 O75604 3/20 0.61
▸ TP53 P04637 1/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ HPGD P15428 2/20 0.60
▸ MAPT P10636 4/20 0.59
▸ GAA P10253 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ POLB P06746 2/20 0.56
▸ DTYMK P23919 1/20 0.43
▸ ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1670332 1.00 MAPK10 (0.70) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL15099930 1.00 MAPK10 (0.70) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL17796243 0.90 TSHR (0.64) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949785 0.89 MAPK10 (0.86) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11960962 0.89 SMN1; SMN2 (0.83) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949768 0.86 MAPK10 (0.78) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949764 0.86 MAPK10 (0.81) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949798 0.86 MAPK10 (0.81) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949838 0.86 MAPK10 (0.72) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1
SCHEMBL11949769 0.85 MAPK10 (0.70) MAPK10HSD17B10SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 — — US disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 — — US disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 — — US disclosed
EP-2485728-B1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH SPA (IT) 2013-07-10 — — EP disclosed
EP-2485728-A1 WNT PATHWAY ANTAGONISTS Siena Biotech S.p.a. (IT) 2012-08-15 — — EP disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 — — US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 — — US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 — — US disclosed
WO-2011042145-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2011-04-14 — — WO disclosed
WO-2011042145-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2011-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196851-A1 WNT PATHWAY ANTAGONISTS WNT1, WNT3A, CTNNB1 MAPK10 231/4885HSD17B10 2237/4885SMN1; SMN2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.